
Michael G Muto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11824489/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. Cancer Research, 2021, 81, 158-173.	0.9	85
2	Triaging abnormal cervical cancer screening tests using p16INK4a detection by ELISA on fresh cervical samples. American Journal of Reproductive Immunology, 2021, 86, e13394.	1.2	2
3	Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1–AKT–p53 Interactions. Cancers, 2021, 13, 2195.	3.7	0
4	Differentiating leiomyosarcoma from leiomyoma: in support of an MR imaging predictive scoring system. Abdominal Radiology, 2021, 46, 4927-4935.	2.1	11
5	Next-Generation Sequencing in the Diagnosis of Metastatic Lesions: Reclassification of a Glioblastoma as an Endometrial Cancer Metastasis to the Brain. Oncologist, 2021, 26, e2102-e2109.	3.7	0
6	Predictive validity of American College of Surgeons: National Surgical Quality Improvement Project risk calculator in patients with ovarian cancer undergoing interval debulking surgery. International Journal of Gynecological Cancer, 2021, 31, 1356-1362.	2.5	3
7	Female adnexal tumor of probable Wolffian Origin – A report of two cases at one institution. Gynecologic Oncology Reports, 2020, 33, 100612.	0.6	1
8	Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer. Gynecologic Oncology, 2020, 159, 687-691.	1.4	6
9	A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome. American Journal of Obstetrics and Gynecology, 2019, 221, 326.e1-326.e7.	1.3	21
10	Infection, thrombosis, and oncologic outcome after interval debulking surgery: Does perioperative blood transfusion matter?. Gynecologic Oncology, 2019, 153, 63-67.	1.4	17
11	Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discovery, 2018, 8, 1404-1421.	9.4	311
12	Assessing Pelvic Epithelial Cancer Risk and Intercepting Early Malignancy. , 2018, , 844-864.		0
13	The Pathology of Pelvic-Ovarian Epithelial (Epithelial-Stromal) Tumors. , 2018, , 865-948.		1
14	Moving beyond "complete surgical resection―and "optimal― Is low-volume residual disease another option for primary debulking surgery?. Gynecologic Oncology, 2018, 150, 233-238.	1.4	21
15	Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated highâ€grade serous carcinomas. Journal of Pathology, 2018, 246, 344-351.	4.5	55
16	Endometrial cancer with an EML4-ALK rearrangement. Journal of Physical Education and Sports Management, 2018, 4, a003020.	1.2	3
17	Comparison of benign peritoneal fluid- and ovarian cancer ascites-derived extracellular vesicle RNA biomarkers. Journal of Ovarian Research, 2018, 11, 20.	3.0	48
18	Frequency of "incidental―serous tubal intraepithelial carcinoma (STIC) in women without a history of or genetic risk factor for high-grade serous carcinoma: A six-year study. Gynecologic Oncology, 2017, 146, 69-73.	1.4	34

MICHAEL G MUTO

#	Article	IF	CITATIONS
19	Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube. BMC Cancer, 2017, 17, 422.	2.6	12
20	The risk of lymphedema after postoperative radiation therapy in endometrial cancer. Journal of Gynecologic Oncology, 2016, 27, e4.	2.2	25
21	Endosalpingiosis: More than just an incidental finding at the time of gynecologic surgery?. Gynecologic Oncology, 2016, 142, 255-260.	1.4	39
22	The Role of Endometrial Biopsy in the Preoperative Detection of Uterine Leiomyosarcoma. Journal of Minimally Invasive Gynecology, 2016, 23, 567-572.	0.6	51
23	Risk Factors for Occult Uterine Sarcoma Among Women Undergoing Minimally Invasive Gynecologic Surgery. Journal of Minimally Invasive Gynecology, 2016, 23, 34-39.	0.6	19
24	Same-Day Discharge After Laparoscopic Hysterectomy for Endometrial Cancer. Annals of Surgical Oncology, 2016, 23, 178-185.	1.5	44
25	Loss of E-cadherin disrupts ovarian epithelial inclusion cyst formation and collective cell movement in ovarian cancer cells. Oncotarget, 2016, 7, 4110-4121.	1.8	32
26	Pinin interacts with C-terminal binding proteins for RNA alternative splicing and epithelial cell identity of human ovarian cancer cells. Oncotarget, 2016, 7, 11397-11411.	1.8	30
27	Does plastic surgical consultation improve the outcome of patients undergoing radical vulvectomy for squamous cell carcinoma of the vulva?. Gynecologic Oncology, 2015, 137, 60-65.	1.4	17
28	Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma. Cancer, 2014, 120, 3154-3158.	4.1	166
29	What is the optimal treatment for obese patients with advanced ovarian carcinoma?. American Journal of Obstetrics and Gynecology, 2014, 211, 231.e1-231.e9.	1.3	8
30	Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma. Gynecologic Oncology, 2014, 135, 54-57.	1.4	2
31	The value of re-exploration in patients with inadvertently morcellated uterine sarcoma. Gynecologic Oncology, 2014, 132, 360-365.	1.4	133
32	Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery?. Gynecologic Oncology, 2013, 129, 69-73.	1.4	24
33	Peritoneal Dissemination Complicating Morcellation of Uterine Mesenchymal Neoplasms. PLoS ONE, 2012, 7, e50058.	2.5	202
34	Laparoscopic Risk-Reducing Salpingo-Oophorectomy: The Brigham and Women's Experience. ISRN Minimally Invasive Surgery, 2012, 2012, 1-7.	0.3	2
35	Differential hRad17 expression by histologic subtype of ovarian cancer. Journal of Ovarian Research, 2011, 4, 6.	3.0	2
36	Disseminated peritoneal leiomyomatosis after laparoscopic supracervical hysterectomy with characteristic molecular cytogenetic findings of uterine leiomyoma. Genes Chromosomes and Cancer, 2010, 49, 1152-1160.	2.8	67

MICHAEL G MUTO

#	Article	IF	CITATIONS
37	Epidemiologic correlates of ovarian cortical inclusion cysts (CICs) support a dual precursor pathway to pelvic epithelial cancer. Gynecologic Oncology, 2009, 115, 108-111.	1.4	24
38	Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. European Journal of Cancer, 2009, 45, 2818-2824.	2.8	44
39	A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecologic Oncology, 2008, 109, 168-173.	1.4	268
40	Risk factors for a serous cancer precursor ("p53 signatureâ€) in women with inherited BRCA mutations. Gynecologic Oncology, 2008, 111, 226-232.	1.4	77
41	Serous Tubal Intraepithelial Carcinoma: Its Potential Role in Primary Peritoneal Serous Carcinoma and Serous Cancer Prevention. Journal of Clinical Oncology, 2008, 26, 4160-4165.	1.6	317
42	Primary Fallopian Tube Malignancies in <i>BRCA</i> -Positive Women Undergoing Surgery for Ovarian Cancer Risk Reduction. Journal of Clinical Oncology, 2007, 25, 3985-3990.	1.6	453
43	Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship. American Journal of Surgical Pathology, 2007, 31, 161-169.	3.7	980
44	Advances in the Recognition of Tubal Intraepithelial Carcinoma. Advances in Anatomic Pathology, 2006, 13, 1-7.	4.3	144
45	The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome. American Journal of Surgical Pathology, 2006, 30, 230-236.	3.7	797
46	Case 18-2005. New England Journal of Medicine, 2005, 352, 2535-2542.	27.0	11
47	Unresorbed Corpora Albicantia Mimicking a Sonographically Solid Ovarian Mass in a Postmenopausal Woman. Journal of Ultrasound in Medicine, 2004, 23, 1523-1526.	1.7	3
48	Small Echogenic Foci in the Ovaries. Journal of Ultrasound in Medicine, 2004, 23, 307-313.	1.7	16
49	k-ras Mutation May Be an Early Event in Mucinous Ovarian Tumorigenesis. International Journal of Gynecological Pathology, 2001, 20, 244-251.	1.4	66
50	Prostasin, a Potential Serum Marker for Ovarian Cancer: Identification Through Microarray Technology. Journal of the National Cancer Institute, 2001, 93, 1458-1464.	6.3	268
51	Genetic Alterations of the WT1 Gene in Papillary Serous Carcinoma of the Peritoneum. Gynecologic Oncology, 2000, 76, 369-372.	1.4	36
52	ras Gene Activation and Infrequent Mutation in Papillary Serous Carcinoma of the Peritoneum. Gynecologic Oncology, 2000, 77, 105-111.	1.4	4
53	Occult Ovarian Tumors in Women With BRCA1 or BRCA2 Mutations Undergoing Prophylactic Oophorectomy. Journal of Clinical Oncology, 2000, 18, 2728-2732.	1.6	182
54	Sporadic Microsatellite Instability Is Specific to Neoplastic and Preneoplastic Endometrial Tissues. American Journal of Clinical Pathology, 2000, 113, 576-582.	0.7	36

MICHAEL G MUTO

#	Article	IF	CITATIONS
55	Distinct Allelic Loss Patterns in Papillary Serous Carcinoma of the Peritoneum. American Journal of Clinical Pathology, 2000, 114, 93-99.	0.7	15
56	A population-based study of BRCA1 and BRCA2 mutations in jewish women with epithelial ovarian cancer. Obstetrics and Gynecology, 1999, 93, 34-37.	2.4	35
57	A Population-Based Study of BRCA1 and BRCA2 Mutations in Jewish Women With Epithelial Ovarian Cancer. Obstetrics and Gynecology, 1999, 93, 34-37.	2.4	17
58	Genetic imbalance on chromosome 17 in papillary serous carcinoma of the peritoneum. Oncogene, 1998, 16, 3455-3459.	5.9	25
59	Molecular Evidence for Multifocal Papillary Serous Carcinoma of the Peritoneum in Patients With Germline BRCA1 Mutations. Journal of the National Cancer Institute, 1998, 90, 841-845.	6.3	123
60	BRCA1 Gene Mutations in Women With Papillary Serous Carcinoma of the Peritoneum. Obstetrics and Gynecology, 1998, 92, 596-600.	2.4	26
61	Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations of <i>BRCA1 </i> . New England Journal of Medicine, 1996, 335, 1413-1416.	27.0	408
62	Monoclonal antibodies used in the detection and treatment of epithelial ovarian cancer. Cancer, 1995, 76, 2016-2027.	4.1	8
63	Characterization of Human Ovarian Surface Epithelial Cells Immortalized by Human Papilloma Viral Oncogenes (HPV-E6E7 ORFs). Experimental Cell Research, 1995, 218, 499-507.	2.6	191
64	p53 Gene Mutation in Human Borderline Epithelial Ovarian Tumors. Journal of the National Cancer Institute, 1994, 86, 1549-1551.	6.3	58
65	Characteristics of Women with a family history of ovarian cancer. I. Galactose consumption and metabolism. Cancer, 1994, 74, 1309-1317.	4.1	29
66	Characteristics of Women with a family history of ovarian cancer. II. Follicular phase hormone levels. Cancer, 1994, 74, 1318-1322.	4.1	16
67	Molecular Genetic Evidence of a Unifocal Origin for Human Serous Ovarian Carcinomas. Gynecologic Oncology, 1993, 48, 5-10.	1.4	71
68	Screening for Ovarian Cancer: The Preliminary Experience of a Familial Ovarian Cancer Center. Gynecologic Oncology, 1993, 51, 12-20.	1.4	66
69	Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125. Gynecologic Oncology, 1992, 45, 265-272.	1.4	38
70	Human anti-murine antibody responses in ovarian cancer patients undergoing radioimmunotherapy with the murine monoclonal antibody OC-125. Gynecologic Oncology, 1990, 38, 244-248.	1.4	17
71	Influence of human antimurine antibody on CA 125 levels in patients with ovarian cancer undergoing radioimmunotherapy or immunoscintigraphy with murine monoclonal antibody OC 125. American Journal of Obstetrics and Cynecology, 1989, 161, 1206-1212.	1.3	25
72	Intraperitoneal radiolabeled OC125 in patients with advanced ovarian cancer. Gynecologic Oncology, 1989, 34, 339-344.	1.4	36